Recent research supports the use of Levagen+
- Treating diabetic‑related peripheral
neuropathic pain - Reducing Headache Pain
- Greater Bioavailability
- Efficacy against multiple variants of the SARS COV-2 Virus
The safety and efficacy of palmitoylethanolamide for treating diabetic‑related peripheral neuropathic pain
This study, published in September 2022 in the journal Inflammopharmacology, from Emily Pickering et al, concluded that the study demonstrated that the PEA formulation reduced diabetic peripheral neuropathic pain and inflammation along with improving mood and sleep. Further studies on the mechanistic effectiveness of PEA as an adjunct medicine and as a monotherapy pain analgesic are warranted.
This study was a single-centre (Australia), quadruple-blinded, placebo-controlled trial with 70 participants receiving 600 mg of PEA or placebo daily, for 8 weeks, with a 94% rate of study participation completion. Primary outcomes were neuropathic pain and specific pain types (the BPI-DPN and NPSI). The secondary outcomes were sleep quality (MOS sleep scale), mood (DASS-21), glucose metabolism and inflammation.
The main results were:
- a significant reduction in total pain and pain interference, in the PEA group compared with the placebo group.
- the sleep index and sub-scores significantly improved.
- depression scores significantly reduced, but not anxiety or stress scores.
- interleukin-6 and elevated C-reactive protein levels significantly reduced in the PEA group, with no differences in fibrinogen between groups (P=0.78) at treatment completion.
- there were no changes in safety pathology parameters, and the treatment was well tolerated.
Efficacy against SARS Variants
The collaborative in-vitro study done by University of Pisa, Italy, Victoria University, Australia and KLEF, India, on Levagen®+ showing it's efficacy against multiple variants of the SARS COV-2 Virus has been published in the reputed Scientific Journal " Viruses ". The journal has an impact factor of 5.048.
Levagen®+ has shown a 70% reduction in the virus entering the cells and also helps to the virus from the cells by dismantling the lipid vesicles enclosing the infected cells, thereby denying sources and energy and protection for the virus.
Increased Bioavailability
Levagen®+ has a published pharmacokinetic study demonstrating it to be 1.75 times more bioavailable than the standard PEA. The cold-water dispersion technology (Lipisperse) allows the particles to freely disperse in aqueous environments, specifically within the stomach, thus increasing absorption.
This allows brands to use a lower dosage in their formulation whilst maintaining the efficacy of this ingredient.
Efficacy of Levagen®+ Compared to Ibuprofen for Reducing Headache Pain Severity and Duration in Healthy Adults:
A Double-Blind, Parallel, Randomized Clinical Trial
This study concluded that the results place PEA as a potential treatment option for
tension-type headaches. For moderate at onset headaches, the comparator group had a greater percentage of pain-free events at 2-hours. However, the time taken to resolve severe headaches was significantly lower in the PEA group than the comparator group (p < 0.05).
Download the Paper
The Advantages of Using Levagen®+
